secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0000950170-25-053745
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.1, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics files preliminary S-1 for resale of shares under Equity Purchase Agreement with Square Gate Capital
--------------------------------------------------------------------------------

- Entered Equity Purchase Agreement and Registration Rights Agreement with Square Gate Capital Master Fund on Feb 20, 2025.
- Filed preliminary S-1 with SEC on April 4, 2025 for resale of Commitment Shares and future issuances.
- SEC letter on April 8, 2025 confirmed it will not review the registration statement.
- Company will request SEC accelerate effectiveness to on or about April 16, 2025.
- Final prospectus to be filed under Rule 424(b)(3) promptly after effectiveness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025053745/0000950170-25-053745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025053745/hcwb-20250414.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-053745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer